Bicara Therapeutics Inc. (NASDAQ:BCAX) Stock Has Consensus Target Price of $32.64 According to Brokerages

Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) have been given an average recommendation of “Moderate Buy” by the sixteen research firms that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, nine have assigned a buy rating and two have issued a strong buy rating on the company. The average 1 year target price among analysts that have covered the stock in the last year is $32.64.

A number of equities research analysts have recently issued reports on BCAX shares. Mizuho increased their price target on shares of Bicara Therapeutics from $18.00 to $20.00 and gave the stock a “neutral” rating in a report on Wednesday, August 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Bicara Therapeutics in a research note on Friday, October 2nd. The Goldman Sachs Group upped their target price on shares of Bicara Therapeutics from $18.00 to $20.00 and gave the stock a “neutral” rating in a report on Wednesday, August 12th. Wedbush increased their target price on shares of Bicara Therapeutics from $30.00 to $33.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 12th. Finally, BMO Capital Markets assumed coverage on shares of Bicara Therapeutics in a report on Tuesday, August 18th. They issued an “outperform” rating and a $35.00 price target for the company.

Insider Transactions at Bicara Therapeutics

In related news, COO Ryan Cohlhepp sold 18,750 shares of the stock in a transaction on Monday, August 10th. The stock was sold at an average price of $27.98, for a total value of $524,625.00. Following the sale, the chief operating officer owned 181,641 shares in the company, valued at approximately $5,082,315.18. This trade represents a 9.36% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Claire Mazumdar sold 10,000 shares of Bicara Therapeutics stock in a transaction on Monday, August 10th. The shares were sold at an average price of $27.98, for a total value of $279,800.00. Following the sale, the chief executive officer directly owned 362,152 shares of the company’s stock, valued at $10,133,012.96. This represents a 2.69% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 58,750 shares of company stock valued at $1,554,800. 13.80% of the stock is currently owned by company insiders.

Institutional Trading of Bicara Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. Caitong International Asset Management Co. Ltd lifted its position in Bicara Therapeutics by 385.3% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 5,775 shares of the company’s stock valued at $97,000 after purchasing an additional 4,585 shares during the last quarter. Arizona State Retirement System purchased a new position in Bicara Therapeutics in the 2nd quarter worth approximately $241,000. Susquehanna Fundamental Investments LLC bought a new position in shares of Bicara Therapeutics in the 2nd quarter worth $272,000. Letko Brosseau & Associates Inc. bought a new position in shares of Bicara Therapeutics in the 4th quarter worth $188,000. Finally, ADAR1 Capital Management LLC purchased a new stake in shares of Bicara Therapeutics during the 2nd quarter valued at $407,000.

Bicara Therapeutics Stock Performance

NASDAQ:BCAX opened at $17.50 on Wednesday. The business’s fifty day moving average is $22.59 and its 200 day moving average is $23.16. The firm has a market cap of $1.16 billion, a price-to-earnings ratio of -5.65 and a beta of -0.70. Bicara Therapeutics has a 52-week low of $13.70 and a 52-week high of $30.99.

Bicara Therapeutics (NASDAQ:BCAX) last issued its earnings results on Tuesday, August 11th. The company reported ($0.82) EPS for the quarter, hitting the consensus estimate of ($0.82). Equities analysts predict that Bicara Therapeutics will post -3.49 EPS for the current fiscal year.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc (NASDAQ: BCAX) is a clinical-stage biotechnology company focused on developing therapies for solid tumors. The company’s approach is designed to address both cancer cells and the tumor microenvironment, which can suppress immune responses and limit the effectiveness of existing treatments.

Bicara’s lead product candidate is ficerafusp alfa, also known as BCA101. It is an investigational bifunctional fusion protein designed to target the epidermal growth factor receptor (EGFR) on tumor cells while blocking transforming growth factor beta (TGF-?), a signaling pathway associated with tumor growth and immune suppression.